SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 254 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $285,598 | +26.1% | 10,359 | +65.7% | 0.00% | 0.0% |
| Q1 2023 | $226,438 | +5.1% | 6,250 | +3.5% | 0.00% | 0.0% |
| Q4 2022 | $215,483 | +7.7% | 6,041 | +2.1% | 0.00% | 0.0% |
| Q3 2022 | $200,000 | +115.1% | 5,914 | +84.6% | 0.00% | 0.0% |
| Q2 2022 | $93,000 | -3.1% | 3,204 | +7.4% | 0.00% | 0.0% |
| Q1 2022 | $96,000 | +190.9% | 2,983 | +163.3% | 0.00% | – |
| Q4 2021 | $33,000 | +17.9% | 1,133 | +8.7% | 0.00% | – |
| Q3 2021 | $28,000 | 0.0% | 1,042 | +16.3% | 0.00% | – |
| Q2 2021 | $28,000 | +16.7% | 896 | -2.2% | 0.00% | – |
| Q1 2021 | $24,000 | +242.9% | 916 | +233.1% | 0.00% | – |
| Q4 2020 | $7,000 | +40.0% | 275 | +22.2% | 0.00% | – |
| Q3 2020 | $5,000 | +25.0% | 225 | +28.6% | 0.00% | – |
| Q2 2020 | $4,000 | 0.0% | 175 | +34.6% | 0.00% | – |
| Q3 2019 | $4,000 | 0.0% | 130 | 0.0% | 0.00% | – |
| Q2 2019 | $4,000 | +300.0% | 130 | +766.7% | 0.00% | – |
| Q2 2018 | $1,000 | – | 15 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |